Intas Biopharma to market PEMETREXED in India
February 25th, 2009
PEMETREXED is used to treat non-small cell lung cancer (NSCLC), the most common type of lung cancer caused primarily from smoking and Mesothelioma, a cancer caused by Asbestos exposure. The brand Pemmet is an inclusion to company’s strong drug portfolio catering to lung cancer, which comprises of Geffy, Gemibine, Carbopa, Taxocare, and Cytax. Lung cancer, accounts for one third of all cancer deaths, cigarette smoking contributing nearly 85-90% of the total cancer deaths.